Figure 5. Effect of 32-134D on the tumor immune microenvironment.
(A–H) C57L mice were injected with Hepa1-6 HCC cells subcutaneously and when tumors reached a volume of 200 mm3, the mice were treated with vehicle or 32-134D (40 mg/kg) by daily intraperitoneal injection for 8 days. Single-cell suspensions prepared from each tumor were analyzed by flow cytometry using fluorescent antibodies against the indicated cell surface proteins. The percentage of cells positive for the indicated markers is shown (mean ± SEM, n = 6). *P < 0.05 (Mann-Whitney test). M-MDSCs and G-MDSCs, monocytic and granulocytic myeloid-derived suppressor cells; TAMs, tumor-associated macrophages.